Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Age-Related Macular Degeneration

Therapeutic area intelligence for Age-Related Macular Degeneration with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
4
Catalysts
0
Companies
1

Companies

Roche →

Assets

iPSC-Derived →
Ophthalmology →

Recent signals(4)

ClinicalJuly 14, 2026

Study on Dark Adaptation for Early Detection of Age-Related Macular Degeneration

A study is evaluating a dark adaptation protocol to identify and monitor early to middle dry AMD over 5 years.

ClinicalJune 26, 2026

Study Evaluates Aflibercept 8 mg for Refractory Age-related Macular Degeneration

Aflibercept 8 mg is being evaluated in a study for its effectiveness in extending injection intervals for patients with refractory exudative age-related macular degeneration.

ClinicalJune 22, 2026

iPSC-Derived RPE Transplantation Trial for Geographic Atrophy in AMD Initiated

A clinical trial is underway to evaluate the safety of autologous transplantation of iPSC-derived retinal pigment epithelium in patients with geographic atrophy associated with age-related macular degeneration.

ClinicalJune 18, 2026

Genentech initiates study on progression of intermediate age-related macular degeneration

Genentech is conducting a multicenter observational study to assess disease progression in intermediate age-related macular degeneration over approximately 3 years.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.